Renalase是新近发现的由肾脏产生的一种单胺氧化酶，可以直接分解儿茶酚胺，renalase减少可导致血液中儿茶酚胺浓度升高，与慢性肾脏疾病（CKD）患者的高血压及心血管并发症密切相关。本研究在前期研究基础上，拟对CKD患者的心力衰竭进展与renalase水平变化进行前瞻性观察，记录主要的心血管临床事件，探讨renalase对CKD患者心血管事件的预测价值；采用renalase基因敲除小鼠与野生型小鼠构建慢肾衰小鼠模型，研究renalase水平变化与慢肾衰进展和心血管并发症的关系，并观察重组renalase对慢肾衰小鼠的替代治疗作用。为探讨renalase的生理功能与病理意义，尤其renalase替代治疗研究奠定实验基础，为CKD乃至高血压的临床治疗提供新的思路。

Renalase, secreted by the kidney, is a novel, recently identified monoamine oxidase and metabolizes circulating catecholamines. Renalase deficiency contributes to the elevated plasma catecholamines' level, which suggests a causal link between renalase deficiency and hypertension, especially cardiovascular risk in patients with CKD. Based on our preliminary study, a prospective observation of patients with CKD will be made to explore the predictive value of renalase to the serious cardiovascular events. To evaluate the role of renalase in chronic renal failure and the replacement therapy effect of renalase, a chroinc renal failure model will be constructed using renalase knockout mouse and wild type mouse. The relationship between renalase and the progression will be studied. This study would provide an experimental basis on revealing the physiological and pathological significance of renalase and the potent effect of the renalase's replacement therapy.